Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by narmacon Oct 08, 2020 6:31am
142 Views
Post# 31685117

RE:RE:RE:RE:RE:RE:Wtf

RE:RE:RE:RE:RE:RE:Wtf,,huummmm,,, I dont think anyone here is losing their minds over the PP,,,they are expressing opinions,,and when you are a long time RVX investor the story just dont seem to change when one looks back. What makes things offensive is the lack of info from DMcC,,he could have noted in his video of late that a PP would be looked at before year end and the reasoning for such when a deal is so close at hand in theory. Seems to me the only thing this does not change would be the price for a buy out for BP,,,,it certainly adds a nice tad of dilution for all present shareholders.

On a side note,,I think it is very obvious to the market that we are not looking at the best business model within the walls of RVX. There would seem to be a few possibilites to bring this science to patients in a more timely fashion and have the synergy to strengthen our balance sheet. But nope,,,not in the cards,,,,as these years pass. There also has to be multiply possiblities around agreements to fulfill moral obligations to best bring epigentics into the public realm. I think the team and its major investors are focusing on themselves. It can be assured they know when PPs are coming,,,,,,however the retail guy ro gal is excluded......even the June/21 warrants are in danger of expiring worthless,,,,,,only 9 months away,,,and you can rest assured the BoM2 will still be in the planning stage at that time,,,,,dead money here at least out to H2..the market sees no urgency.... jmo
<< Previous
Bullboard Posts
Next >>